Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Working Memory-Related Effective Connectivity in Huntington's Disease Patients.

Lahr J, Minkova L, Tabrizi SJ, Stout JC, Klöppel S, Scheller E; TrackOn-HD Investigators.

Front Neurol. 2018 Jun 4;9:370. doi: 10.3389/fneur.2018.00370. eCollection 2018.

PMID:
29915555
2.

Testing a longitudinal compensation model in premanifest Huntington's disease.

Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, Johnson EB, Durr A, Roos RAC, Leavitt BR, Mills JA, Stout JC, Scahill RI, Tabrizi SJ, Rees G; Track-On investigators .

Brain. 2018 May 17. doi: 10.1093/brain/awy122. [Epub ahead of print]

3.

An image-based model of brain volume biomarker changes in Huntington's disease.

Wijeratne PA, Young AL, Oxtoby NP, Marinescu RV, Firth NC, Johnson EB, Mohan A, Sampaio C, Scahill RI, Tabrizi SJ, Alexander DC.

Ann Clin Transl Neurol. 2018 Apr 2;5(5):570-582. doi: 10.1002/acn3.558. eCollection 2018 May.

4.

Overlap between age-at-onset and disease-progression determinants in Huntington disease.

Aziz NA, van der Burg JMM, Tabrizi SJ, Landwehrmeyer GB.

Neurology. 2018 Jun 12;90(24):e2099-e2106. doi: 10.1212/WNL.0000000000005690. Epub 2018 May 9.

5.

Natural biological variation of white matter microstructure is accentuated in Huntington's disease.

Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M.

Hum Brain Mapp. 2018 Apr 22. doi: 10.1002/hbm.24191. [Epub ahead of print]

PMID:
29682858
6.

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.

Minkova L, Gregory S, Scahill RI, Abdulkadir A, Kaller CP, Peter J, Long JD, Stout JC, Reilmann R, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S; TRACK-HD Investigators.

Neuroimage Clin. 2017 Oct 25;17:312-324. doi: 10.1016/j.nicl.2017.10.023. eCollection 2018.

7.

Clinical Features of Huntington's Disease.

Ghosh R, Tabrizi SJ.

Adv Exp Med Biol. 2018;1049:1-28. doi: 10.1007/978-3-319-71779-1_1.

PMID:
29427096
8.

Predicting clinical diagnosis in Huntington's disease: An imaging polymarker.

Mason SL, Daws RE, Soreq E, Johnson EB, Scahill RI, Tabrizi SJ, Barker RA, Hampshire A.

Ann Neurol. 2018 Mar;83(3):532-543. doi: 10.1002/ana.25171. Epub 2018 Mar 13.

9.

Test-Retest Reliability of Measures Commonly Used to Measure Striatal Dysfunction across Multiple Testing Sessions: A Longitudinal Study.

Palmer CE, Langbehn D, Tabrizi SJ, Papoutsi M.

Front Psychol. 2018 Jan 12;8:2363. doi: 10.3389/fpsyg.2017.02363. eCollection 2017.

10.

Neurofilament light protein in blood predicts regional atrophy in Huntington disease.

Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RA, Zetterberg H, Tabrizi SJ, Scahill RI, Wild EJ; TRACK-HD Study Group.

Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24.

11.

Motor cortex synchronization influences the rhythm of motor performance in premanifest huntington's disease.

Casula EP, Mayer IMS, Desikan M, Tabrizi SJ, Rothwell JC, Orth M.

Mov Disord. 2018 Mar;33(3):440-448. doi: 10.1002/mds.27285. Epub 2018 Jan 22.

PMID:
29356133
12.

Huntington disease.

Ghosh R, Tabrizi SJ.

Handb Clin Neurol. 2018;147:255-278. doi: 10.1016/B978-0-444-63233-3.00017-8.

PMID:
29325616
13.

Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays.

Hensman Moss DJ, Robertson N, Farmer R, Scahill RI, Haider S, Tessari MA, Flynn G, Fischer DF, Wild EJ, Macdonald D, Tabrizi SJ.

PLoS One. 2017 Dec 22;12(12):e0189891. doi: 10.1371/journal.pone.0189891. eCollection 2017.

14.

Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study.

Papoutsi M, Weiskopf N, Langbehn D, Reilmann R, Rees G, Tabrizi SJ.

Hum Brain Mapp. 2018 Mar;39(3):1339-1353. doi: 10.1002/hbm.23921. Epub 2017 Dec 13.

15.

Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes.

McColgan P, Gregory S, Seunarine KK, Razi A, Papoutsi M, Johnson E, Durr A, Roos RAC, Leavitt BR, Holmans P, Scahill RI, Clark CA, Rees G, Tabrizi SJ; Track-On HD Investigators.

Biol Psychiatry. 2018 Mar 1;83(5):456-465. doi: 10.1016/j.biopsych.2017.10.019. Epub 2017 Oct 26.

16.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

PMID:
29142089
17.

Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice.

Bondulich MK, Jolinon N, Osborne GF, Smith EJ, Rattray I, Neueder A, Sathasivam K, Ahmed M, Ali N, Benjamin AC, Chang X, Dick JRT, Ellis M, Franklin SA, Goodwin D, Inuabasi L, Lazell H, Lehar A, Richard-Londt A, Rosinski J, Smith DL, Wood T, Tabrizi SJ, Brandner S, Greensmith L, Howland D, Munoz-Sanjuan I, Lee SJ, Bates GP.

Sci Rep. 2017 Oct 27;7(1):14275. doi: 10.1038/s41598-017-14290-3.

18.

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease.

Johnson EB, Gregory S, Johnson HJ, Durr A, Leavitt BR, Roos RA, Rees G, Tabrizi SJ, Scahill RI.

Front Neurol. 2017 Oct 10;8:519. doi: 10.3389/fneur.2017.00519. eCollection 2017.

19.

Gene suppression approaches to neurodegeneration.

Ghosh R, Tabrizi SJ.

Alzheimers Res Ther. 2017 Oct 5;9(1):82. doi: 10.1186/s13195-017-0307-1. Review.

20.

Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ; Track-HD and Track-On Investigators.

JAMA Neurol. 2017 Nov 1;74(11):1352-1360. doi: 10.1001/jamaneurol.2017.2107.

PMID:
28975278
21.

Structural imaging in premanifest and manifest Huntington disease.

Scahill RI, Andre R, Tabrizi SJ, Aylward EH.

Handb Clin Neurol. 2017;144:247-261. doi: 10.1016/B978-0-12-801893-4.00020-1. Review.

PMID:
28947121
22.

Therapies targeting DNA and RNA in Huntington's disease.

Wild EJ, Tabrizi SJ.

Lancet Neurol. 2017 Oct;16(10):837-847. doi: 10.1016/S1474-4422(17)30280-6. Epub 2017 Sep 12. Review. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

23.

Design optimization for clinical trials in early-stage manifest Huntington's disease.

Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C; TRACK-HD Investigators.

Mov Disord. 2017 Nov;32(11):1610-1619. doi: 10.1002/mds.27122. Epub 2017 Sep 14.

PMID:
28906031
24.

Huntington's disease: a clinical review.

McColgan P, Tabrizi SJ.

Eur J Neurol. 2018 Jan;25(1):24-34. doi: 10.1111/ene.13413. Epub 2017 Sep 22. Review.

PMID:
28817209
25.

The reliability of commonly used electrophysiology measures.

Brown KE, Lohse KR, Mayer IMS, Strigaro G, Desikan M, Casula EP, Meunier S, Popa T, Lamy JC, Odish O, Leavitt BR, Durr A, Roos RAC, Tabrizi SJ, Rothwell JC, Boyd LA, Orth M.

Brain Stimul. 2017 Nov - Dec;10(6):1102-1111. doi: 10.1016/j.brs.2017.07.011. Epub 2017 Jul 31.

PMID:
28807846
26.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.

PMID:
28642124
27.

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.

Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7.

28.

Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes.

Stuitje G, van Belzen MJ, Gardiner SL, van Roon-Mom WMC, Boogaard MW; REGISTRY Investigators of the European Huntington Disease Network, Tabrizi SJ, Roos RAC, Aziz NA.

Brain. 2017 Jul 1;140(7):e42. doi: 10.1093/brain/awx122. No abstract available.

PMID:
28549075
29.

Measuring compensation in neurodegeneration using MRI.

Gregory S, Long JD, Tabrizi SJ, Rees G.

Curr Opin Neurol. 2017 Aug;30(4):380-387. doi: 10.1097/WCO.0000000000000469. Review.

PMID:
28537993
30.

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.

Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4676-E4685. doi: 10.1073/pnas.1614943114. Epub 2017 May 22.

31.

Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.

Marras C, Lang A, van de Warrenburg BP, Sue CM, Tabrizi SJ, Bertram L, Mercimek-Mahmutoglu S, Ebrahimi-Fakhari D, Warner TT, Durr A, Assmann B, Lohmann K, Kostic V, Klein C.

Mov Disord. 2017 May;32(5):724-725. doi: 10.1002/mds.27045. No abstract available.

PMID:
28513081
32.

The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients.

Neueder A, Landles C, Ghosh R, Howland D, Myers RH, Faull RLM, Tabrizi SJ, Bates GP.

Sci Rep. 2017 May 2;7(1):1307. doi: 10.1038/s41598-017-01510-z.

33.

Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.

Miller JRC, Pfister EL, Liu W, Andre R, Träger U, Kennington LA, Lo K, Dijkstra S, Macdonald D, Ostroff G, Aronin N, Tabrizi SJ.

Sci Rep. 2017 Apr 24;7:46740. doi: 10.1038/srep46740.

34.

Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease.

McColgan P, Seunarine KK, Gregory S, Razi A, Papoutsi M, Long JD, Mills JA, Johnson E, Durr A, Roos RAC, Leavitt BR, Stout JC, Scahill RI, Clark CA, Rees G, Tabrizi SJ, Investigators TTH.

JCI Insight. 2017 Apr 20;2(8). pii: 92641. doi: 10.1172/jci.insight.92641. [Epub ahead of print]

35.

Operationalizing compensation over time in neurodegenerative disease.

Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, Papoutsi M, Mills JA, Durr A, Leavitt BR, Roos RAC, Stout JC, Scahill RI, Langbehn DR, Tabrizi SJ, Rees G.

Brain. 2017 Apr 1;140(4):1158-1165. doi: 10.1093/brain/awx022. No abstract available.

36.

Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease.

Hensman Moss DJ, Flower MD, Lo KK, Miller JR, van Ommen GB, 't Hoen PA, Stone TC, Guinee A, Langbehn DR, Jones L, Plagnol V, van Roon-Mom WM, Holmans P, Tabrizi SJ.

Sci Rep. 2017 Mar 21;7:44849. doi: 10.1038/srep44849.

37.

Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease.

McColgan P, Razi A, Gregory S, Seunarine KK, Durr A, A C Roos R, Leavitt BR, Scahill RI, Clark CA, Langbehn DR, Rees G, Tabrizi SJ; Track On-HD Investigators.

Hum Brain Mapp. 2017 Jun;38(6):2819-2829. doi: 10.1002/hbm.23527. Epub 2017 Mar 15.

38.

White matter predicts functional connectivity in premanifest Huntington's disease.

McColgan P, Gregory S, Razi A, Seunarine KK, Gargouri F, Durr A, Roos RA, Leavitt BR, Scahill RI, Clark CA, Tabrizi SJ, Rees G; and the Track On‐HD Investigators, Coleman A, Decolongon J, Fan M, Petkau T, Jauffret C, Justo D, Lehericy S, Nigaud K, Valabrègue R, Choonderbeek A, Hart EP, Hensman Moss DJ, Crawford H, Johnson E, Papoutsi M, Berna C, Reilmann R, Weber N, Stout J, Labuschagne I, Landwehrmeyer B, Orth M, Johnson H.

Ann Clin Transl Neurol. 2017 Jan 16;4(2):106-118. doi: 10.1002/acn3.384. eCollection 2017 Feb.

39.

DNA repair in the trinucleotide repeat disorders.

Jones L, Houlden H, Tabrizi SJ.

Lancet Neurol. 2017 Jan;16(1):88-96. doi: 10.1016/S1474-4422(16)30350-7. Review.

PMID:
27979358
40.

Corrigendum to "Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers" [Neurobiol. Dis. 83 (2015) 115-121].

Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE, Tabrizi SJ, Piccini P.

Neurobiol Dis. 2017 Feb;98:162. doi: 10.1016/j.nbd.2016.12.003. Epub 2016 Dec 8. No abstract available.

PMID:
27939917
41.

Validation of a prognostic index for Huntington's disease.

Long JD, Langbehn DR, Tabrizi SJ, Landwehrmeyer BG, Paulsen JS, Warner J, Sampaio C.

Mov Disord. 2017 Feb;32(2):256-263. doi: 10.1002/mds.26838. Epub 2016 Nov 28.

42.

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.

Rodrigues FB, Byrne LM, McColgan P, Robertson N, Tabrizi SJ, Zetterberg H, Wild EJ.

PLoS One. 2016 Sep 22;11(9):e0163479. doi: 10.1371/journal.pone.0163479. eCollection 2016.

43.

Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!

Klein C, Lang A, van de Warrenburg BP, Sue CM, Tabrizi SJ, Bertram L, Mercimek-Mahmutoglu S, Ebrahimi-Fakhari D, Warner TT, Durr A, Assmann B, Kostic V, Lohmann K, Marras C; International Parkinson and Movement Disorder Society Task Force on Classification and Nomenclature of Genetic Movement Disorders.

Mov Disord. 2016 Nov;31(11):1760-1762. doi: 10.1002/mds.26763. Epub 2016 Sep 13. No abstract available.

PMID:
27619077
44.

Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.

Wilson H, Niccolini F, Haider S, Marques TR, Pagano G, Coello C, Natesan S, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M.

J Neurol Sci. 2016 Sep 15;368:243-8. doi: 10.1016/j.jns.2016.07.033. Epub 2016 Jul 15.

PMID:
27538642
45.

Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.

Orth M, Gregory S, Scahill RI, Mayer IS, Minkova L, Klöppel S, Seunarine KK, Boyd L, Borowsky B, Reilmann R, Bernhard Landwehrmeyer G, Leavitt BR, Roos RA, Durr A, Rees G, Rothwell JC, Langbehn D, Tabrizi SJ; TRACK-On Investigators.

Hum Brain Mapp. 2016 Dec;37(12):4615-4628. doi: 10.1002/hbm.23332. Epub 2016 Aug 1.

PMID:
27477323
46.

George Huntington: a legacy of inquiry, empathy and hope.

Wexler A, Wild EJ, Tabrizi SJ.

Brain. 2016 Aug;139(Pt 8):2326-33. doi: 10.1093/brain/aww165. Epub 2016 Jul 14. No abstract available.

47.

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.

Rodrigues FB, Byrne L, McColgan P, Robertson N, Tabrizi SJ, Leavitt BR, Zetterberg H, Wild EJ.

J Neurochem. 2016 Oct;139(1):22-5. doi: 10.1111/jnc.13719. Epub 2016 Sep 20.

48.

Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease.

Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O'Regan A, Queller S, Frost C, Leavitt BR, Dürr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC; TRACK-HD Investigators.

J Int Neuropsychol Soc. 2016 Jul;22(6):595-608. doi: 10.1017/S1355617716000321. Epub 2016 May 23.

PMID:
27211109
49.

RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation.

Miller JR, Lo KK, Andre R, Hensman Moss DJ, Träger U, Stone TC, Jones L, Holmans P, Plagnol V, Tabrizi SJ.

Hum Mol Genet. 2016 Jul 15;25(14):2893-2904. Epub 2016 May 11.

50.

Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.

Marras C, Lang A, van de Warrenburg BP, Sue CM, Tabrizi SJ, Bertram L, Mercimek-Mahmutoglu S, Ebrahimi-Fakhari D, Warner TT, Durr A, Assmann B, Lohmann K, Kostic V, Klein C.

Mov Disord. 2016 Apr;31(4):436-57. doi: 10.1002/mds.26527. Review.

PMID:
27079681

Supplemental Content

Loading ...
Support Center